Bullfrog AI Holdings, Inc. Share Price

Equities

BFRG

US12021E1091

Biotechnology & Medical Research

Market Closed - Nasdaq 02:00:01 14/05/2024 am IST 5-day change 1st Jan Change
2.987 USD +3.36% Intraday chart for Bullfrog AI Holdings, Inc. -1.09% -8.37%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 0.01 0.83 Sales 2023 0.06 5.43 Capitalization 1.99Cr 165.89Cr
Net income 2022 -20L -17Cr Net income 2023 -50L -42Cr EV / Sales 2022 * -
Net Debt 2022 15.21L 13Cr Net cash position 2023 26.25L 22Cr EV / Sales 2023 26,52,89,369 x
P/E ratio 2022 *
-
P/E ratio 2023
-3.68 x
Employees 8
Yield 2022 *
-
Yield 2023
-
Free-Float 66.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.36%
1 week-1.09%
Current month-4.87%
1 month-2.70%
3 months-37.25%
6 months+1.25%
Current year-8.37%
More quotes
1 week
2.80
Extreme 2.8
3.15
1 month
2.67
Extreme 2.67
3.24
Current year
2.42
Extreme 2.4201
8.35
1 year
2.36
Extreme 2.36
8.35
3 years
2.36
Extreme 2.36
9.50
5 years
2.36
Extreme 2.36
9.50
10 years
2.36
Extreme 2.36
9.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 01/17/01
Director of Finance/CFO 66 01/21/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 55 15/23/15
Director/Board Member 71 15/23/15
Chief Executive Officer 55 01/17/01
More insiders
Date Price Change Volume
13/24/13 2.987 +3.36% 93,965
10/24/10 2.89 -3.02% 78,056
09/24/09 2.98 +1.36% 83,163
08/24/08 2.94 +2.44% 57,943
07/24/07 2.87 -4.97% 49,356

Delayed Quote Nasdaq, May 14, 2024 at 02:00 am IST

More quotes
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW